Artis BioSolutions to acquire Syngoi from Buenavista and Columbus

Artis BioSolutions has reached an agreement to buy Syngoi Technologies, the Basque synthetic DNA specialist, from backers Buenavista Equity Partners and Columbus Venture Partners. The sale, announced in Madrid, remains subject to final sign-off by the Spanish Council of Ministers and will fold Syngoi into Artis’s global operations to establish a direct presence in the United States.

Syngoi Technologies, founded in 2021 and based in Zamudio (Bizkaia), operates as a CDMO focused on synthetic DNA for advanced therapies. Its platform supports critical inputs for mRNA vaccines, gene therapies and gene-editing medicines by delivering shorter lead times and higher purity DNA compared with many legacy processes. After a 2024 capital increase, Syngoi expanded capacity and now supports more than 25 concurrent client projects.

The 2024 funding round brought strategic and financial partners together: Buenavista invested via its BV Healthcare Growth Innvierte I vehicle, while Columbus Venture Partners participated through its life-science funds and industrial partner Asahi Kasei Medical also joined the syndicate. That injection was explicitly aimed at scaling manufacturing capability to meet accelerating demand from biopharma innovators.

Nuria Osés, Managing Partner on Buenavista’s private equity team, framed the divestment as the natural next stage for the business: supporting the founders through scale-up and realising value for the fund’s investors while positioning Syngoi for international growth under Artis’s ownership. The transaction, she said, validates the fund’s strategy of backing technology-led healthcare growth stories in Spain.

Market context makes the deal notable. Demand for synthetic DNA and oligonucleotide production capacity has surged as developers of mRNA vaccines, gene therapies and advanced biologics push towards clinical and commercial supply. CDMO services in this niche are seeing double-digit growth and strong pricing power because quality and scale are barriers to entry. For Spanish biotech, cross-border exits that create a US operational footprint are an increasingly common route to accelerate commercial traction.

For Buenavista Equity Partners, which launched BV Healthcare Growth Innvierte I in 2024 with commitments of €100 million (hard cap €150 million), the sale fits a playbook of building domestic healthcare champions and harvesting value through strategic industrial buyers. The fund targets 10–12 companies with tickets up to €15 million, focusing on biotech, therapeutics, diagnostics and scale-up manufacturing.

Assuming regulatory clearance, integration into Artis BioSolutions is expected to accelerate Syngoi’s US-facing commercial activity and expand access for US biopharma clients seeking synthetic DNA supply. The deal underscores growing investor appetite for specialised manufacturing assets that underpin next-generation therapies and highlights Spain’s maturing life-science ecosystem as a source of exportable capability.